SHCS

Swiss HIV Cohort Study

& Swiss Mother and Child HIV Cohort Study

Bot et al., Treat all, treat fast: time from HIV diagnosis to treatment initiation in Switzerland, 1996 – 2025

Bot et al., Treat all, treat fast: time from HIV diagnosis to treatment initiation in Switzerland, 1996 – 2025

18th November, 2026

Treat All, Treat Fast: Time From HIV Diagnosis to Treatment Initiation in Switzerland, 1996–2025

Starting antiretroviral therapy (ART) immediately after HIV diagnosis is a clinical and public health priority, but it is unclear how quickly and how equally the “treat all” strategy has been put into practice at a national level. In this study among participants of the Swiss HIV Cohort Study, Bot et al. assessed time from HIV diagnosis to ART initiation, and the sociodemographic and clinical characteristics associated with a shorter time to treatment start.

The study included 7’525 ART-naive participants diagnosed with HIV between 1996 and 2025. Factors associated with ART initiation were analysed among participants diagnosed from 2006 onwards and enrolled within 6 months of diagnosis, separately for the periods 2006–2016 and 2017–2025. Kaplan-Meier methods were used to estimate time to ART initiation, and time-updated Cox proportional hazards models were used to identify associated characteristics.

Overall, 93.1% of participants had initiated ART by the end of 2025. Median time from diagnosis to ART initiation dropped sharply from 983 days in 2005 to 28 days in 2015, and reached 12 days in 2025, and 42.2% of participants started ART within 1 week. Differences by CD4 cell count disappeared over time, with median times below 3 weeks in all CD4 strata by 2025. However, in 2017–2025, participants from Africa (hazard ratio 0.62, 95% confidence interval 0.42–0.92) and the Americas (hazard ratio 0.59, 95% confidence interval 0.41–0.85) were less likely than Europeans to start ART at any given time, and people who inject drugs consistently had the lowest probability of ART initiation, although absolute differences were at most about 1 week.

In summary, universal treatment was rapidly adopted in Switzerland, with a clear shift toward rapid and equitable ART initiation. Remaining disparities by viral load, region of origin, and among people who inject drugs should be monitored, and highlight the importance of addressing language, structural, and engagement-related barriers so that all people with HIV benefit equally from rapid ART.

PubMed